Illumina and Tempus have entered a partnership to advance the clinical adoption of next-generation sequencing tests by leveraging artificial intelligence (AI).
The collaboration will integrate Illumina’s AI technologies with Tempus’s extensive multimodal data platform to enhance genomic algorithms.
It will ultimately accelerate the adoption of molecular testing in clinical settings.
The partnership will use Tempus’s multimodal data to improve Illumina’s AI-driven molecular analysis technologies.
Also, it will generate insights supporting the sequencing and standardisation of comprehensive genomic profiling and other molecular tests across major diseases.
Illumina chief commercial officer Everett Cunningham said: “In the era of true precision medicine, every patient who is battling complex disease should be routed to the optimal therapy based on molecular insights.
“We envision a world where the full range of molecular profiling is available as part of the standard of care, not just in cancer, but in cardiology, neurology, immunology, and every other category of disease.”
Tempus chief commercial officer Terron Bruner said: “By expanding our collaboration with Illumina, we are combining our strengths in technology and data analytics with their strengths in developing new sequencing technologies to drive forward innovation and advance precision medicine.”
Illumina, a US-based medical technology company, specialises in DNA sequencing and array-based technologies, serving research, clinical, and applied markets.
Tempus offers AI-enabled precision medicine solutions to deliver personalised patient care and supports the discovery, development, and delivery of optimal therapeutics.
The collaboration builds on a longstanding relationship between the two companies, focusing on developing tools and assays to address gaps in testing needs.
Its efforts span pre-emptive screening, therapy selection, health economics, and bioinformatics pipelines to enhance patient outcomes and research capabilities.
In August last year, Tempus expanded its commercial partnership with US-based genomic sequencing and analytics provider Personalis.
In October last year, Illumina introduced the MiSeq i100 Series of benchtop systems, designed to simplify next-generation sequencing for laboratories.
